Image de couverture de livre

Letter: Reassessing Tenofovir Alafenamide Use Throughout Pregnancy—A New Horizon in Hepatitis B Therapy. Authors' Reply

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Xingfei Pan, Calvin Q. Pan
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers With Hepatitis B
par: Xingfei Pan, et autres
Publié: (2025)

Letters on “Efficacy and Safety of Tenofovir Alafenamide ( TAF ) and Tenofovir Disoproxil Fumarate ( TDF ) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment.” Authors' Reply
par: Grace Lai‐Hung Wong, et autres
Publié: (2025)

Letter: “Tenofovir Alafenamide—The ‘Star of Potential’ for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials.” Authors' Reply
par: Maria Buti
Publié: (2025)

Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment
par: Grace Lai‐Hung Wong, et autres
Publié: (2025)

Letter on “Efficacy and Safety of Tenofovir Alafenamide ( TAF ) and Tenofovir Disoproxil Fumarate ( TDF ) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment”
par: Yan Liu, et autres
Publié: (2025)

Letter: Tenofovir Alafenamide—The “Star of Potential” for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials
par: YaoYao Dai, et autres
Publié: (2025)

Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline–A Step Toward Functional Cure or a Marginal Margin?
par: Yao‐Chun Hsu, et autres
Publié: (2026)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
par: Francisco Idalsoaga, et autres
Publié: (2025)

Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score‐Matched Study Using Linear Mixed‐Effects Models
par: Takashi Kumada, et autres
Publié: (2026)

Featured Cover
par: Xingfei Pan, et autres
Publié: (2025)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
par: Pinelopi Arvaniti, et autres
Publié: (2025)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks—Authors' Reply
par: Rui Huang, et autres
Publié: (2025)

Letter: Boosting non‐invasive tests—Opportunities and challenges from resmetirom
par: Gong Feng, et autres
Publié: (2024)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations. Authors' Reply'
par: Alberto Ferrarese, et autres
Publié: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
par: Lukas Burghart, et autres
Publié: (2026)

Letter: Reconsidering Tenofovir Disoproxil Fumarate Use in Light of Emerging Safety Evidence
par: Priyadarshini Zula, et autres
Publié: (2026)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
par: Francisco Idalsoaga, et autres
Publié: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply
par: Francisco Idalsoaga, et autres
Publié: (2025)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination. Authors' Reply
par: Anupam Kumar Singh, et autres
Publié: (2026)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate—Authors' Reply
par: Ying‐Nan Tsai, et autres
Publié: (2025)

Letter: Methodological Gaps Undermine Conclusions on Electronic Nose Use for Colorectal Cancer Detection—Authors' Reply
par: Milou. L. M. van Riswijk, et autres
Publié: (2025)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy—Authors' Reply
par: Tanat Saeoui, et autres
Publié: (2025)

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
par: Shintaro Akiyama, et autres
Publié: (2025)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition? Authors' Reply
par: Irene Spinelli, et autres
Publié: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
par: J. M. Schattenberg, et autres
Publié: (2026)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
par: Virginia Solitano, et autres
Publié: (2024)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
par: Jian Wang, et autres
Publié: (2025)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
par: Ying‐Nan Tsai, et autres
Publié: (2025)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
par: Mohamed El‐Kassas, et autres
Publié: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
par: Nina Dominik, et autres
Publié: (2024)

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimisation. Authors' Reply
par: Sarah Flatley
Publié: (2026)

Letter: Enhancing Risk‐Adapted Colorectal Cancer Screening for People With Diabetes—Authors' Reply
par: Teresa Seum, et autres
Publié: (2025)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
par: Hong‐Li Liu, et autres
Publié: (2026)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
par: Yu‐Sheng Lin, et autres
Publié: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
par: Yuki Utakata, et autres
Publié: (2026)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’—Authors' Reply
par: Ning Yu, et autres
Publié: (2025)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
par: Chachrit Khunsriraksakul, et autres
Publié: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
par: Juan Macias, et autres
Publié: (2025)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
par: Luis Antonio Díaz, et autres
Publié: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
par: Jeffrey D McCurdy, et autres
Publié: (2025)